FDA pulls opioid from market over misuse concerns
BMJ 2017; 357 doi: https://doi.org/10.1136/bmj.j2860 (Published 13 June 2017) Cite this as: BMJ 2017;357:j2860- Owen Dyer
- Montreal
The US Food and Drug Administration has asked Endo Pharmaceuticals to withdraw its Opana ER formulation of oxymorphone amid concerns over a mounting epidemic of opioid misuse. It is the first time the FDA has made such a request, which could require court action to enforce.
The Dublin based drug manufacturer did not immediately say whether it would comply. Endo said in a statement that it is “reviewing the request and is evaluating the full range of potential options.”
The FDA’s request sent Endo’s shares tumbling 13.4% on Wall Street. The request was foreshadowed in March, when an FDA …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.